川芎嗪联合阿托伐他汀治疗肺动脉高压的临床疗效分析

Analysis on Clinical Effect of Atorvastatin Plus Ligustrazine on Pulmonary Hypertension

目的:观察川芎嗪联合阿托伐他汀治疗肺动脉高压的临床疗效及安全性。方法:将96例肺动脉高压患者随机分成两组,其中治疗组48人,对照组48人。治疗组患者在常规治疗基础上采川芎嗪联合阿托伐他汀治疗,对照组患者在常规治疗基础上单采用阿托伐他汀治疗,通过检测平均动脉压(mAP)、平均肺动脉压(mPAP)、肺血管阻力(PVR)、心脏指数(CI)、左心室射血分数(LVER)、Borg呼吸困难指数(Borg dyspnea)、6分钟步行距离(6TWD)以及肺功能升级(WHO FC)等指标评价其疗效。结果:两组患者经过6个月的治疗后,mPAP、PVR与治疗前相比显著降低,而CI、LVEF和6MWD均显著升高,差异均有统计学意义(P<0.05),治疗前后两组mAP与Borg呼吸困难指数均没有统计学差异(P>0.05),治疗组的mAP、LVEF以及6TWD与对照组相比差异有统计学意义(P<0.05)。结论:川芎嗪联合阿托伐他汀治疗充肺动脉高压临床疗效优于单纯应用阿托伐他汀。

Objective： To explore the clinical effect and security of atorvastatin combined with ligustrazine in the treatment of pulmonary hypertension. Methods： 96 patients with pulmonary hypertension were randomly divided into the treating group（48 cases） and control group （48 cases）, patients in the treating group received the treatment ofatorvastatin combined with ligustrazine while patients in the control group received the treatment of atorvastatin. MAP, mPAP, PVR, CI, LVER, Borg dyspnea, 6TWD, WHO FC were detected and compared to evaluate the clinical effect. Results： After 6 months＇ treatment, both mPAP and PVR decreased significantly in comparison with before treatment, while CI, LVEF and 6 MWD increased significantly （P〈0.05）, no significant difference of mAP and Borg dyspnea was observed before and after treatment in both groups （P〉0.05）; mAP, LVEF and 6TWD of the treating group showed significant difference with that of control group （P〈0.05）. Conclusion： The clinical efficacy of the atorvastatin plus ligustrazine was superior to atorvastatin for treating pulmonary hypertension.